Anastrozole and Letrozole

Overview

Aromatase Inhibitors (AI) are effective for secondary prevention of breast cancer and may soon replace tamoxifen as first-line therapy in the treatment of hormone-sensitive breast cancer. However, because these medications produce a marked reduction in serum estrogen levels, this is likely to result in an increased rate of bone loss and risk of developing osteoporosis and fractures in postmenopausal women treated with these agents. Indeed, substantial bone loss has been reported in several large clinical trials of AIs. Osteoporosis drugs are available that could prevent this loss, but they have frequent side effects and are expensive. Thus, treating all women receiving AIs might not be the most appropriate and cost-effective approach. A better approach might be to select women at highest risk of bone loss and only treat them with antiresorptive agents. The proposed pilot study will evaluate women who receive anastrozole or letrozole therapy, are receiving adequate amounts of calcium and vitamin D and have baseline normal or moderately low bone mass in order to determine if early changes in bone turnover markers correlate with bone loss at one year. If data from this pilot protocol support our hypothesis, then we would propose a larger trial to confirm it. The ultimate aim is to predict which women are at higher risk of bone loss and therefore treat them earlier with bone-sparing agents, while those with lower risk could be monitored on conservative therapy.

Full Title of Study: “Effect Of Anastrozole And Letrozole On Bone Turnover Markers And Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer: A Pilot Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2011

Arms, Groups and Cohorts

  • 644-001
    • Women treated for breast cancer who will be starting Arimidex or Femara

Clinical Trial Outcome Measures

Primary Measures

  • bone density
    • Time Frame: baseline, 6 months, 12 months

Secondary Measures

  • bone markers
    • Time Frame: baseline, 1 month, 3 month, 6 month, 12 month

Participating in This Clinical Trial

Inclusion Criteria

  • Postmenopausal women with diagnosis of breast cancer – have not started Arimidex or Femara yet, but will be starting . Exclusion Criteria:

  • History of metastasis – History of chronic kidney – Liver GI disease – Disorders affecting calcium metabolism

Gender Eligibility: Female

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • UConn Health
  • Collaborator
    • Connecticut Breast Health Initiative
  • Provider of Information About this Clinical Study
    • Principal Investigator: Pamela Taxel, Associate Professor of Medicine – UConn Health
  • Overall Official(s)
    • Pamela Taxel, MD, Principal Investigator, UConn Health

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.